New obesity drug CRB-913 enters human testing
Disease control
Ongoing
This study tests a new drug called CRB-913 for weight loss in people with obesity. It involves 252 participants and has two parts: first, measuring how the drug works in healthy adults, then comparing three doses against a placebo over 12 weeks. The goal is to check safety and ho…
Phase: PHASE1 • Sponsor: Corbus Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC